Chan C, Andreotti D, Cox B, Dymock B W, Hutson J L, Keeling S E, McCarthy A D, Procopiou P A, Ross B C, Sareen M, Scicinski J J, Sharratt P J, Snowden M A, Watson N S
Glaxo Wellcome Research & Development, Medicines Research Centre, Stevenage, Herfordshire, UK.
J Med Chem. 1996 Jan 5;39(1):207-16. doi: 10.1021/jm9504969.
Squalestatins without either the hydroxy group at C-4 or the carboxylic acid at C-3 or C-4 were prepared and evaluated for their ability to inhibit rat liver microsomal squalene synthase (SQS) in vitro. These modifications were well tolerated for compounds with the 4,6-dimethyloctenoate ester at C-6 (S1 series). However in analogues without the C-6 ester (H1 series), removal of the C-4 hydroxy group gave compounds with reduced potency, whereas decarboxylation at C-3 resulted in a dramatic loss of SQS inhibitory activity. In comparison with S1 1, C-4 deoxyS1 3 and C-3 decarboxyS1 10 have shorter in vivo durations of action on the inhibition of hepatic cholesterol biosynthesis in rats. C-4 deoxyS1 3 retains good serum cholesterol-lowering ability in marmosets, while C-3 decarboxyS1 10 showed only a marginal effect even at high dose.
制备了在C-4位没有羟基或者在C-3或C-4位没有羧酸的鲨他汀,并对它们在体外抑制大鼠肝脏微粒体角鲨烯合酶(SQS)的能力进行了评估。对于在C-6位带有4,6-二甲基辛烯酸酯的化合物(S1系列),这些修饰具有良好的耐受性。然而,在没有C-6酯的类似物(H1系列)中,去除C-4羟基会使化合物的效力降低,而在C-3位脱羧则导致SQS抑制活性急剧丧失。与S1 1相比,C-4脱氧S1 3和C-3脱羧S1 10对大鼠肝脏胆固醇生物合成抑制的体内作用持续时间较短。C-4脱氧S1 3在狨猴中保留了良好的降低血清胆固醇的能力,而C-3脱羧S1 10即使在高剂量下也仅显示出微弱的效果。